Abstract
Folates are one-carbon donors essential for synthesizing purines, pyrimidines, serine, and methionine. They correspond to anionic hydrophilic molecules essential for DNA synthesis in mammalian cells. The latter cells lack the capacity to synthesize folates. In some patients, high dosages of antifolate drugs (eg: methotrexate, pemetrexed) used in cancer chemotherapy alter the keratinocytes, endothelial cells and Factor XIIIa+ dermal dendrocytes in a range of various severities. Such conditions clinically designed under the heading antifolate cytotoxic skin reaction (ACSR) occasionally resemble the toxic epidermal necrolysis (TEN) / Stevens-Johnson syndrome (SJS) spectrum. Whether or not the TEN/SJS presentation of ACSR is a regular condition similar to that induced by other drugs or a variant condition supported by a unique pathomechanism is unsettled.
Keywords: Antifolate, methotrexate, pemetrexed, cancer, folate metabolism, toxic epidermal necrolysis, Stevens-Johnson syndrome, Folates, necrosis, lymphocytes, macrophages
Current Drug Safety
Title:Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Volume: 7 Issue: 5
Author(s): Claudine Pierard-Franchimont, Marianne Lesuisse, Philippe Humbert, Philippe Delvenne and Gerald E. Pierard
Affiliation:
Keywords: Antifolate, methotrexate, pemetrexed, cancer, folate metabolism, toxic epidermal necrolysis, Stevens-Johnson syndrome, Folates, necrosis, lymphocytes, macrophages
Abstract: Folates are one-carbon donors essential for synthesizing purines, pyrimidines, serine, and methionine. They correspond to anionic hydrophilic molecules essential for DNA synthesis in mammalian cells. The latter cells lack the capacity to synthesize folates. In some patients, high dosages of antifolate drugs (eg: methotrexate, pemetrexed) used in cancer chemotherapy alter the keratinocytes, endothelial cells and Factor XIIIa+ dermal dendrocytes in a range of various severities. Such conditions clinically designed under the heading antifolate cytotoxic skin reaction (ACSR) occasionally resemble the toxic epidermal necrolysis (TEN) / Stevens-Johnson syndrome (SJS) spectrum. Whether or not the TEN/SJS presentation of ACSR is a regular condition similar to that induced by other drugs or a variant condition supported by a unique pathomechanism is unsettled.
Export Options
About this article
Cite this article as:
Pierard-Franchimont Claudine, Lesuisse Marianne, Humbert Philippe, Delvenne Philippe and E. Pierard Gerald, Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy, Current Drug Safety 2012; 7 (5) . https://dx.doi.org/10.2174/1574886311207050005
DOI https://dx.doi.org/10.2174/1574886311207050005 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Viral Vectors for Gene-Directed Enzyme Prodrug Therapy
Current Gene Therapy Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Modulating Fatty Acid Metabolism and the AMP-Activated Protein Kinase Pathway as a Target for Obesity Therapy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design Computational & Statistical Methodologies to Identify Biomarkers in Cancer
Current Cancer Therapy Reviews G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Pemetrexed: Potential Role in the Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
Current Drug Targets Role of miRNAs in Cancer Diagnostics and Therapy: A Recent Update
Current Pharmaceutical Design Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma
Current Cancer Drug Targets